Our latest preprint, “GALILEO™ Generatively Expands Chemical Space and Achieves One-Shot Identification of a Library of Novel, Specific, Next-Generation Broad-Spectrum Antiviral Compounds at High Hit Rates,” highlights how GALILEO™ seamlessly bridges biology and chemistry to accelerate the creation of new therapeutics.

From Biology to Chemistry: End-to-End AI Discovery

In earlier work, GALILEO™ identified the Thumb-1 site—a cryptic, allosteric antiviral target conserved across RNA viruses. Building on this, GALILEO™ explored 52 trillion molecules to identify 12 novel chemical entities (NCEs) with broad-spectrum antiviral activity.

Key Results

• 100% Hit Rate: All 12 NCEs showed activity against HCV and/or human Coronavirus 229E in vitro.

• Enhanced Specificity: Up to 15,000-fold specificity improvements, minimizing off-target effects.

• Efficiency: Faster and more cost-effective than traditional pipelines.

By uniting target discovery and generative chemistry, GALILEO™ redefines what’s possible in drug development.

A New Standard in Drug Discovery

This preprint builds on GALILEO™’s earlier success with MDL-001, a first-in-class broad-spectrum antiviral. Now, GALILEO™ delivers new breakthroughs in generative AI, expanding chemical space and designing entirely novel therapeutics to meet future health challenges.